Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
18,515
archived clinical trials in
Lymphoma

Dietary and Exercise Interventions in Preventing Cardiovascular Disease in Younger Survivors of Leukemia, Lymphoma, or Brain Tumors
Effect of Non-Pharmacologic Interventions on Risk Factors of Cardiovascular Disease in Survivors of Childhood Leukemia, Lymphoma and Brain Tumor
Status: Enrolling
Updated:  12/2/2014
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Dietary and Exercise Interventions in Preventing Cardiovascular Disease in Younger Survivors of Leukemia, Lymphoma, or Brain Tumors
Effect of Non-Pharmacologic Interventions on Risk Factors of Cardiovascular Disease in Survivors of Childhood Leukemia, Lymphoma and Brain Tumor
Status: Enrolling
Updated: 12/2/2014
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Pilot Study of Brentuximab Vedotin (SGN-35) in Patients With MF With Variable CD30 Expression Level
Exploratory Pilot Study of Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level
Status: Enrolling
Updated:  2/5/2015
Stanford University School of Medicine
mi
from
Stanford, CA
Pilot Study of Brentuximab Vedotin (SGN-35) in Patients With MF With Variable CD30 Expression Level
Exploratory Pilot Study of Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level
Status: Enrolling
Updated: 2/5/2015
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Use of Hyperbaric Oxygen Therapy to Improve Umbilical Cord Blood Stem Cell Homing and Subsequent Engraftment
A Pilot Study to Determine the Safety and Efficacy of Using Hyperbaric Oxygen Therapy to Improve Umbilical Cord Blood Stem Cell Homing and Subsequent Engraftment
Status: Enrolling
Updated:  2/13/2015
University of Kansas Medical Center
mi
from
Kansas City, KA
Use of Hyperbaric Oxygen Therapy to Improve Umbilical Cord Blood Stem Cell Homing and Subsequent Engraftment
A Pilot Study to Determine the Safety and Efficacy of Using Hyperbaric Oxygen Therapy to Improve Umbilical Cord Blood Stem Cell Homing and Subsequent Engraftment
Status: Enrolling
Updated: 2/13/2015
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients
A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients
Status: Enrolling
Updated:  2/18/2015
Yale Cancer Center
mi
from
New Haven, CT
A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients
A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients
Status: Enrolling
Updated: 2/18/2015
Yale Cancer Center
mi
from
New Haven, CT
Click here to add this to my saved trials
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated:  3/10/2015
Pfizer Investigational Site
mi
from
Little Rock, AR
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated: 3/10/2015
Pfizer Investigational Site
mi
from
Little Rock, AR
Click here to add this to my saved trials
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated:  3/10/2015
Pfizer Investigational Site
mi
from
Fountain Valley, CA
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated: 3/10/2015
Pfizer Investigational Site
mi
from
Fountain Valley, CA
Click here to add this to my saved trials
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated:  3/10/2015
Pfizer Investigational Site
mi
from
Los Angeles, CA
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated: 3/10/2015
Pfizer Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated:  3/10/2015
Pfizer Investigational Site
mi
from
New Milford, CT
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated: 3/10/2015
Pfizer Investigational Site
mi
from
New Milford, CT
Click here to add this to my saved trials
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated:  3/10/2015
Pfizer Investigational Site
mi
from
Washington,
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated: 3/10/2015
Pfizer Investigational Site
mi
from
Washington,
Click here to add this to my saved trials
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated:  3/10/2015
Pfizer Investigational Site
mi
from
Boca Raton, FL
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated: 3/10/2015
Pfizer Investigational Site
mi
from
Boca Raton, FL
Click here to add this to my saved trials
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated:  3/10/2015
Pfizer Investigational Site
mi
from
Honolulu, HI
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated: 3/10/2015
Pfizer Investigational Site
mi
from
Honolulu, HI
Click here to add this to my saved trials
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated:  3/10/2015
Pfizer Investigational Site
mi
from
Chicago, IL
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated: 3/10/2015
Pfizer Investigational Site
mi
from
Chicago, IL
Click here to add this to my saved trials
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated:  3/10/2015
Pfizer Investigational Site
mi
from
Morristown, NJ
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated: 3/10/2015
Pfizer Investigational Site
mi
from
Morristown, NJ
Click here to add this to my saved trials
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated:  3/10/2015
Pfizer Investigational Site
mi
from
Buffalo, NY
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated: 3/10/2015
Pfizer Investigational Site
mi
from
Buffalo, NY
Click here to add this to my saved trials
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated:  3/10/2015
Pfizer Investigational Site
mi
from
New York, NY
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated: 3/10/2015
Pfizer Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated:  3/10/2015
Pfizer Investigational Site
mi
from
Rochester, NY
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated: 3/10/2015
Pfizer Investigational Site
mi
from
Rochester, NY
Click here to add this to my saved trials
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated:  3/10/2015
Pfizer Investigational Site
mi
from
Portland, OR
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated: 3/10/2015
Pfizer Investigational Site
mi
from
Portland, OR
Click here to add this to my saved trials
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated:  3/10/2015
Pfizer Investigational Site
mi
from
Upland, PA
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated: 3/10/2015
Pfizer Investigational Site
mi
from
Upland, PA
Click here to add this to my saved trials
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated:  3/10/2015
Pfizer Investigational Site
mi
from
Austin, TX
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated: 3/10/2015
Pfizer Investigational Site
mi
from
Austin, TX
Click here to add this to my saved trials
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated:  3/10/2015
Pfizer Investigational Site
mi
from
Grapevine, TX
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated: 3/10/2015
Pfizer Investigational Site
mi
from
Grapevine, TX
Click here to add this to my saved trials
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated:  3/10/2015
Pfizer Investigational Site
mi
from
Houston, TX
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated: 3/10/2015
Pfizer Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated:  3/10/2015
Pfizer Investigational Site
mi
from
Temple, TX
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated: 3/10/2015
Pfizer Investigational Site
mi
from
Temple, TX
Click here to add this to my saved trials
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated:  3/10/2015
Pfizer Investigational Site
mi
from
Seattle, WA
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated: 3/10/2015
Pfizer Investigational Site
mi
from
Seattle, WA
Click here to add this to my saved trials
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated:  3/10/2015
Pfizer Investigational Site
mi
from
Buenos Aires,
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)
Status: Enrolling
Updated: 3/10/2015
Pfizer Investigational Site
mi
from
Buenos Aires,
Click here to add this to my saved trials
Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
A Randomized, Open-Label, Multi-Center, Phase 2 Study of Zevalin ([90Y]- Ibritumomab Tiuxetan) Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab- Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  6/2/2015
Alta Bates Summit Medical Center-Herrick
mi
from
Berkeley, CA
Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
A Randomized, Open-Label, Multi-Center, Phase 2 Study of Zevalin ([90Y]- Ibritumomab Tiuxetan) Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab- Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 6/2/2015
Alta Bates Summit Medical Center-Herrick
mi
from
Berkeley, CA
Click here to add this to my saved trials
Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
A Randomized, Open-Label, Multi-Center, Phase 2 Study of Zevalin ([90Y]- Ibritumomab Tiuxetan) Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab- Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  6/2/2015
Providence Saint-Joseph Medical Center
mi
from
Burbank, CA
Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
A Randomized, Open-Label, Multi-Center, Phase 2 Study of Zevalin ([90Y]- Ibritumomab Tiuxetan) Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab- Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 6/2/2015
Providence Saint-Joseph Medical Center
mi
from
Burbank, CA
Click here to add this to my saved trials
Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
A Randomized, Open-Label, Multi-Center, Phase 2 Study of Zevalin ([90Y]- Ibritumomab Tiuxetan) Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab- Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  6/2/2015
Halifax Health- Center for Oncology
mi
from
Daytona Beach, FL
Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
A Randomized, Open-Label, Multi-Center, Phase 2 Study of Zevalin ([90Y]- Ibritumomab Tiuxetan) Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab- Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 6/2/2015
Halifax Health- Center for Oncology
mi
from
Daytona Beach, FL
Click here to add this to my saved trials
Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
A Randomized, Open-Label, Multi-Center, Phase 2 Study of Zevalin ([90Y]- Ibritumomab Tiuxetan) Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab- Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  6/2/2015
Rush University Medical Center
mi
from
Chicago, IL
Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
A Randomized, Open-Label, Multi-Center, Phase 2 Study of Zevalin ([90Y]- Ibritumomab Tiuxetan) Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab- Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 6/2/2015
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
A Randomized, Open-Label, Multi-Center, Phase 2 Study of Zevalin ([90Y]- Ibritumomab Tiuxetan) Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab- Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  6/2/2015
Oncology Specialists
mi
from
Park Ridge, IL
Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
A Randomized, Open-Label, Multi-Center, Phase 2 Study of Zevalin ([90Y]- Ibritumomab Tiuxetan) Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab- Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 6/2/2015
Oncology Specialists
mi
from
Park Ridge, IL
Click here to add this to my saved trials
Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
A Randomized, Open-Label, Multi-Center, Phase 2 Study of Zevalin ([90Y]- Ibritumomab Tiuxetan) Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab- Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  6/2/2015
Hackensack Medical Center
mi
from
Hackensack, NJ
Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
A Randomized, Open-Label, Multi-Center, Phase 2 Study of Zevalin ([90Y]- Ibritumomab Tiuxetan) Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab- Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 6/2/2015
Hackensack Medical Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
A Randomized, Open-Label, Multi-Center, Phase 2 Study of Zevalin ([90Y]- Ibritumomab Tiuxetan) Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab- Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  6/2/2015
West Virginia University, WVU Healthcare
mi
from
Morgantown, WV
Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
A Randomized, Open-Label, Multi-Center, Phase 2 Study of Zevalin ([90Y]- Ibritumomab Tiuxetan) Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab- Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 6/2/2015
West Virginia University, WVU Healthcare
mi
from
Morgantown, WV
Click here to add this to my saved trials
Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
A Randomized, Open-Label, Multi-Center, Phase 2 Study of Zevalin ([90Y]- Ibritumomab Tiuxetan) Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab- Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  6/2/2015
Loyola University Chicago
mi
from
Maywood, IL
Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
A Randomized, Open-Label, Multi-Center, Phase 2 Study of Zevalin ([90Y]- Ibritumomab Tiuxetan) Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab- Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 6/2/2015
Loyola University Chicago
mi
from
Maywood, IL
Click here to add this to my saved trials
Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
A Randomized, Open-Label, Multi-Center, Phase 2 Study of Zevalin ([90Y]- Ibritumomab Tiuxetan) Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab- Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  6/2/2015
University of Massachusetts Worcester
mi
from
Worcester, MA
Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
A Randomized, Open-Label, Multi-Center, Phase 2 Study of Zevalin ([90Y]- Ibritumomab Tiuxetan) Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab- Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 6/2/2015
University of Massachusetts Worcester
mi
from
Worcester, MA
Click here to add this to my saved trials
Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma
Study of Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma (CTCL)
Status: Enrolling
Updated:  6/19/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma
Study of Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma (CTCL)
Status: Enrolling
Updated: 6/19/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide
Busulfan (IV) and Fludarabine Followed by Post-allogeneic Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies.
Status: Enrolling
Updated:  7/2/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide
Busulfan (IV) and Fludarabine Followed by Post-allogeneic Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies.
Status: Enrolling
Updated: 7/2/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  7/3/2015
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 7/3/2015
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  7/3/2015
Mayo Clinic, Jacksonville
mi
from
Jacksonville, FL
Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 7/3/2015
Mayo Clinic, Jacksonville
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  7/3/2015
Rush-Copley Cancer Care Center
mi
from
Aurora, IL
Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 7/3/2015
Rush-Copley Cancer Care Center
mi
from
Aurora, IL
Click here to add this to my saved trials
Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  7/3/2015
St. Joseph Medical Center
mi
from
Bloomington, IL
Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 7/3/2015
St. Joseph Medical Center
mi
from
Bloomington, IL
Click here to add this to my saved trials
Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  7/3/2015
Graham Hospital
mi
from
Canton, IL
Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 7/3/2015
Graham Hospital
mi
from
Canton, IL
Click here to add this to my saved trials
Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  7/3/2015
Memorial Hospital
mi
from
Carthage, IL
Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 7/3/2015
Memorial Hospital
mi
from
Carthage, IL
Click here to add this to my saved trials
Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  7/3/2015
Eureka Community Hospital
mi
from
Eureka, IL
Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 7/3/2015
Eureka Community Hospital
mi
from
Eureka, IL
Click here to add this to my saved trials
Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  7/3/2015
Galesburg Clinic, PC
mi
from
Galesburg, IL
Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 7/3/2015
Galesburg Clinic, PC
mi
from
Galesburg, IL
Click here to add this to my saved trials
Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  7/3/2015
Galesburg Cottage Hospital
mi
from
Galesburg, IL
Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 7/3/2015
Galesburg Cottage Hospital
mi
from
Galesburg, IL
Click here to add this to my saved trials
Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  7/3/2015
Mason District Hospital
mi
from
Havana, IL
Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 7/3/2015
Mason District Hospital
mi
from
Havana, IL
Click here to add this to my saved trials
Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  7/3/2015
Hopedale Medical Complex
mi
from
Hopedale, IL
Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 7/3/2015
Hopedale Medical Complex
mi
from
Hopedale, IL
Click here to add this to my saved trials
Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  7/3/2015
Joliet Oncology-Hematology Associates, Limited - West
mi
from
Joliet, IL
Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 7/3/2015
Joliet Oncology-Hematology Associates, Limited - West
mi
from
Joliet, IL
Click here to add this to my saved trials
Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  7/3/2015
McDonough District Hospital
mi
from
Macomb, IL
Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 7/3/2015
McDonough District Hospital
mi
from
Macomb, IL
Click here to add this to my saved trials
Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  7/3/2015
Clinical Research Facility
mi
from
Moline, IL
Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 7/3/2015
Clinical Research Facility
mi
from
Moline, IL
Click here to add this to my saved trials
Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study
Status: Enrolling
Updated:  7/3/2015
Community Cancer Center
mi
from
Normal, IL
Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer
The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study
Status: Enrolling
Updated: 7/3/2015
Community Cancer Center
mi
from
Normal, IL
Click here to add this to my saved trials